{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:19:36Z","timestamp":1785435576596,"version":"3.56.0"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173618"],"award-info":[{"award-number":["82173618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82173618"],"award-info":[{"award-number":["82173618"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objective: The aim was to evaluate the cost-effectiveness of self-paid vaccination using Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV) in China, as well as their inclusion in China\u2019s National Immunization Program (NIP), and to determine the most cost-effective initial vaccination age under this inclusion strategy. Methods: Based on the ZONA model, a Markov model was developed by incorporating pain severity levels for herpes zoster (HZ) and postherpetic neuralgia (PHN), allowing for dynamic transitions between health states. The model evaluated the cost-effectiveness of six vaccination strategies from a societal perspective. Economic evaluations were conducted using the incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and incremental cost-utility ratio (ICUR). The robustness of the results was verified through sensitivity analysis. Results: In the self-paid scenario, both RZV and ZVL were economically viable for preventing HZ. However, neither was cost-effective in preventing PHN. When included in the NIP, initiating RZV vaccination at age 50 demonstrated dominance (higher quality-adjusted life years and lower costs), with an ICER of \u22123826 CNY per HZ case prevented, \u221238,669 CNY per PHN case prevented, and an ICUR of \u221211,128 CNY per QALY gained. Subgroup analysis indicated that initiating RZV vaccination at age 50 offered the best cost-effectiveness, while age 70 was the most cost-saving option. Conclusions: Generally, RZV demonstrates greater cost-effectiveness compared to ZVL. Incorporating RZV into the NIP, starting at age 70, is the optimal strategy to reduce the burden of HZ and PHN and improve healthcare resource allocation in China.<\/jats:p>","DOI":"10.3390\/vaccines14070587","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios"],"prefix":"10.3390","volume":"14","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8825-1593","authenticated-orcid":false,"given":"Song","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7110-5971","authenticated-orcid":false,"given":"Tianming","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-582X","authenticated-orcid":false,"given":"Cairong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM199607043350107","article-title":"Postherpetic neuralgia\u2014Pathogenesis, treatment, and prevention","volume":"335","author":"Kost","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198209000-00003","article-title":"Population-based study of herpes zoster and its sequelae","volume":"61","author":"Ragozzino","year":"1982","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.321.7264.794","article-title":"Prevalence of postherpetic neuralgia after a first episode of herpes zoster: Prospective study with long term follow up","volume":"321","author":"Helgason","year":"2000","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Li, Y., An, Z., Yin, D., Liu, Y., Huang, Z., Xu, J., Ma, Y., Tu, Q., Li, Q., and Wang, H. (2016). Disease Burden Due to Herpes Zoster among Population Aged \u226550 Years Old in China: A Community Based Retrospective Survey. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152660"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00435395","article-title":"The Nottingham Health Profile as a measure of quality of life in zoster patients: Convergent and discriminant validity","volume":"3","author":"Mauskopf","year":"1994","journal-title":"Qual. Life Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J. Pain."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1232910","DOI":"10.1126\/science.1232910","article-title":"Accelerating next-generation vaccine development for global disease prevention","volume":"340","author":"Koff","year":"2013","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jaad.2007.08.046","article-title":"Herpes zoster: Epidemiology, natural history, and common complications","volume":"57","author":"Weinberg","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/infdis\/jiaa300","article-title":"Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination","volume":"224","author":"Hastie","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","unstructured":"Dingxiangyuan (DXY) (2025, July 01). Package Insert for Herpes Zoster Attenuated Live Vaccine. Available online: https:\/\/drugs.dxy.cn\/pc\/drug\/eu8Irmepepm9Rhzuexg72hUofEA==?ky=%E5%B8%A6%E7%8A%B6%E7%96%B1%E7%96%AB%E8%8B%97."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jiang, B., Wang, Q., Wang, Z., Xu, Y., Yang, T., Yang, W., Jia, M., and Feng, L. (2022). Willingness to accept herpes zoster vaccines and the influencing factors in China. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07840-2"},{"key":"ref_16","first-page":"899","article-title":"A study on knowledge, attitude, and vaccination behavior of herpes zoster vaccine among urban residents in selected areas of China","volume":"44","author":"Wang","year":"2023","journal-title":"Chin. J. Epidemiol."},{"key":"ref_17","first-page":"125","article-title":"Analysis of vaccination willingness and related factors of influenza, pneumonia, and herpes zoster vaccines among people aged 50 years and above in Minhang District, Shanghai","volume":"56","author":"Lu","year":"2022","journal-title":"Chin. J. Prev. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E932","DOI":"10.1503\/cmaj.190274","article-title":"Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: A modelling study","volume":"191","author":"Drolet","year":"2019","journal-title":"Can. Med. Assoc. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2024.05.016","article-title":"The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study","volume":"42","author":"Kim","year":"2024","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wolff, E., Widgren, K., Scalia Tomba, G., Roth, A., Lep, T., and Andersson, S. (2021). Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251644"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, J., Jin, P., Jin, H., Wang, Q., Zhu, F., and Li, J. (2024). Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine. Vaccines, 12.","DOI":"10.3390\/vaccines12080872"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","article-title":"Assessment of the potential public health impact of Herpes Zoster vaccination in Germany","volume":"13","author":"Curran","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1478-7547-8-7","article-title":"A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK","volume":"8","author":"Moore","year":"2010","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"ref_24","unstructured":"National Health Commission of the People\u2019s Republic of China (2024). Statistical communiqu\u00e9 on the development of health and wellness in China in 2023. Chin. J. Viral Dis., 14, 416\u2013424."},{"key":"ref_25","first-page":"50","article-title":"Epidemiological characteristics of initial outpatient cases of herpes zoster in Changping District, Beijing, 2021","volume":"38","author":"Zhu","year":"2023","journal-title":"Bull. Dis. Control Prev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458517708663","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands","volume":"23","author":"Uitdehaag","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1016\/j.vaccine.2021.07.029","article-title":"Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population","volume":"39","author":"Carrico","year":"2021","journal-title":"Vaccine"},{"key":"ref_29","first-page":"432","article-title":"Analysis of epidemiological characteristics of herpes zoster in urban areas of Yichang City from 2016 to 2017 based on the health management big data platform","volume":"25","author":"Jiang","year":"2019","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e011405","DOI":"10.1136\/bmjgh-2022-011405","article-title":"Vaccine pricing strategies in China","volume":"8","author":"Zhang","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_31","unstructured":"National People\u2019s Congress of the People\u2019s Republic of China (2025, July 01). Vaccine Administration Law of the People\u2019s Republic of China, Available online: http:\/\/www.npc.gov.cn\/npc\/c2\/c30834\/201907\/t20190702_299244.html."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1016\/j.vaccine.2010.07.064","article-title":"Seasonal influenza vaccine supply and target vaccinated population in China, 2004\u20132009","volume":"28","author":"Feng","year":"2010","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2351584","DOI":"10.1080\/21645515.2024.2351584","article-title":"Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults \u2265 50 years: A randomized, placebo-controlled trial","volume":"20","author":"Zhu","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0272989X03256883","article-title":"The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis","volume":"23","author":"Zaric","year":"2003","journal-title":"Med. Decis. Mak."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jpain.2010.02.020","article-title":"Predictors of postherpetic neuralgia among patients with herpes zoster: A prospective study","volume":"11","author":"Drolet","year":"2010","journal-title":"J. Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijid.2015.03.022","article-title":"Predictors of postherpetic neuralgia in patients with herpes zoster: A pooled analysis of prospective cohort studies from North and Latin America and Asia","volume":"34","author":"Kawai","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.pain.2007.02.004","article-title":"Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: Prospective prognostic study","volume":"132","author":"Opstelten","year":"2007","journal-title":"Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/oep\/gpaa004","article-title":"Health capital provision and human capital accumulation","volume":"72","author":"Azarnert","year":"2020","journal-title":"Oxf. Econ. Pap."},{"key":"ref_40","first-page":"1481","article-title":"A Meta-analysis of vaccination willingness and influencing factors for herpes zoster in adults","volume":"41","author":"Cheng","year":"2025","journal-title":"J. Prev. Med. Inf."},{"key":"ref_41","first-page":"138","article-title":"Comparison of basic information and market application data of two herpes zoster vaccines","volume":"14","author":"Liu","year":"2024","journal-title":"Med. Front."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2020.12.013","article-title":"Incidence and disease burden of herpes zoster in the population aged \u226550 years in China: Data from an integrated health care network","volume":"82","author":"Sun","year":"2021","journal-title":"J. Infect."},{"key":"ref_43","first-page":"75","article-title":"Direct economic burden of herpes zoster and postherpetic neuralgia in urban population of Yichang City","volume":"10","author":"Yang","year":"2020","journal-title":"Chin. J. Viral Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gater, A., Abetz-Webb, L., Carroll, S., Mannan, A., Serpell, M., and Johnson, R. (2014). Burden of herpes zoster in the UK: Findings from the zoster quality of life (ZQOL) study. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-402"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/ageing\/afj048","article-title":"A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia","volume":"35","author":"Sadosky","year":"2006","journal-title":"Age Ageing"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/gerona\/glaa127","article-title":"Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults","volume":"76","author":"Schmader","year":"2021","journal-title":"J. Gerontol. Ser. A"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:26:06Z","timestamp":1782905166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070587"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070587","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}